BR0100946A - Metabólitos de hexahidropirazolo[4,3-c] piridina - Google Patents
Metabólitos de hexahidropirazolo[4,3-c] piridinaInfo
- Publication number
- BR0100946A BR0100946A BR0100946-0A BR0100946A BR0100946A BR 0100946 A BR0100946 A BR 0100946A BR 0100946 A BR0100946 A BR 0100946A BR 0100946 A BR0100946 A BR 0100946A
- Authority
- BR
- Brazil
- Prior art keywords
- metabolites
- oxo
- benzyl
- racemic
- pharmaceutically acceptable
- Prior art date
Links
- ARIZMZOLGKBQRK-UHFFFAOYSA-N 2,3,3a,4,5,6-hexahydro-1h-pyrazolo[4,3-c]pyridine Chemical class C1NCC2CNNC2=C1 ARIZMZOLGKBQRK-UHFFFAOYSA-N 0.000 title 1
- 239000002207 metabolite Substances 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- 230000003287 optical effect Effects 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003981 vehicle Substances 0.000 abstract 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 229940047889 isobutyramide Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940063238 premarin Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Patente de Invenção: "METABóLITOS DEHEXAHIDROPIRAZOLO[4,3C] PIRIDINA". A invençãoproporciona metabólitos do composto2-amino-N-[2(3a(R)-benzil-2-metil-3-oxo-2,3,3a,4,6,7-hexahidro-pirazolo-[4,3-c] piridin-5il)-1-(R)-benzil-oximetil-2-oxo-etil]-isobutiramida, asmisturas racêmicasdiastereoméricas e isómeros ópticos destes, assuas pró-drogas e os sais farmaceuticamente aceitáveis dosmetabólitos, misturas racêmicasdiastereoméricas, isómeros ópticose pró-drogas; composições farmacêuticas destes; e métodos deutilizar os metabólitos e as formulações no tratamento de doençasrelacionadas com níveis reduzidos do hormónio do crescimento. Ainvenção proporciona ainda um kit compreendendo um metabólitodo composto2-amino-N-[2-(3a(R)-benzil-2-metil-3-oxo-2,3,3a,4,6,7hexahidro-pirazolo-[4,3-c]piridin-5-il)-1 -(R)-benzil-oximetil-2-oxo-etíl]-isobutiramida,uma mistura racêmica-diastereomérica ou um isómero óptico deste,uma sua pró-droga ou um sal farmaceuticamente aceitável dometabólito, mistura racómica-diastereamérica, isómero óptico oupró-droga e um excipiente, veículo ou diluente farmaceuticamenteaceitável em uma primeira forma de dosagem; estrogênio,progesterona Premarin<32>, ou um bisfosfonato, preferencialmentealendronato, e um excipiente, veículo ou diluentefarmaceuticamente aceitável em uma segunda forma de dosagem;e uma embalagem.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18796500P | 2000-03-09 | 2000-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0100946A true BR0100946A (pt) | 2001-10-30 |
Family
ID=22691219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0100946-0A BR0100946A (pt) | 2000-03-09 | 2001-03-09 | Metabólitos de hexahidropirazolo[4,3-c] piridina |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6531449B2 (pt) |
| EP (1) | EP1132388A3 (pt) |
| JP (1) | JP3529736B2 (pt) |
| BR (1) | BR0100946A (pt) |
| CA (1) | CA2339528C (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020165816A1 (en) * | 2001-05-02 | 2002-11-07 | Barz Graydon Lee | Method for stochastically modeling electricity prices |
| WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| US7957507B2 (en) | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
| US8232535B2 (en) | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
| CN101268467B (zh) | 2005-07-22 | 2012-07-18 | 断层放疗公司 | 用于评估治疗计划的实施中的质量保证标准的方法和系统 |
| CA2616301A1 (en) * | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | Method and system for evaluating delivered dose |
| US7639853B2 (en) | 2005-07-22 | 2009-12-29 | Tomotherapy Incorporated | Method of and system for predicting dose delivery |
| AU2006272742A1 (en) * | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | System and method of delivering radiation therapy to a moving region of interest |
| CA2616138A1 (en) * | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | System and method of monitoring the operation of a medical device |
| JP5060476B2 (ja) * | 2005-07-22 | 2012-10-31 | トモセラピー・インコーポレーテッド | 放射線療法を受けている患者の呼吸位相を検出するシステムおよび方法 |
| JP2009514559A (ja) | 2005-07-22 | 2009-04-09 | トモセラピー・インコーポレーテッド | 線量体積ヒストグラムを用いて輪郭構造を生成するシステムおよび方法 |
| US7567694B2 (en) * | 2005-07-22 | 2009-07-28 | Tomotherapy Incorporated | Method of placing constraints on a deformation map and system for implementing same |
| EP1907065B1 (en) * | 2005-07-22 | 2012-11-07 | TomoTherapy, Inc. | Method and system for adapting a radiation therapy treatment plan based on a biological model |
| EP1906827A4 (en) * | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | SYSTEM AND METHOD FOR EVALUATING A DOSE ADMINISTERED BY A RADIATION THERAPY SYSTEM |
| CA2616306A1 (en) * | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | Method and system for processing data relating to a radiation therapy treatment plan |
| US8442287B2 (en) | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
| EP3175886B1 (en) | 2005-07-23 | 2018-06-27 | TomoTherapy, Inc. | Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch |
| EP2962309B1 (en) | 2013-02-26 | 2022-02-16 | Accuray, Inc. | Electromagnetically actuated multi-leaf collimator |
| US20160187724A1 (en) * | 2013-10-08 | 2016-06-30 | Sharp Kabushiki Kaisha | Image display device |
| RU2695649C2 (ru) * | 2014-08-05 | 2019-07-25 | Раквалиа Фарма Инк. | Производные серина в качестве агонистов грелиновых рецепторов |
| MX2021011885A (es) * | 2019-03-29 | 2022-04-18 | Juniper Pharmaceuticals Inc N/K/A Catalent Jnp Inc | Anillos intravaginales segmentados de eva que contienen progesterona. |
| WO2025245189A1 (en) * | 2024-05-22 | 2025-11-27 | Regents Of The University Of Minnesota | Methods for rapid preparation of microbes for microbiota transplantation therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| UA64751C2 (uk) * | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| US6541634B2 (en) * | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
-
2001
- 2001-03-06 EP EP01302043A patent/EP1132388A3/en not_active Withdrawn
- 2001-03-07 CA CA002339528A patent/CA2339528C/en not_active Expired - Fee Related
- 2001-03-08 US US09/801,964 patent/US6531449B2/en not_active Expired - Fee Related
- 2001-03-09 BR BR0100946-0A patent/BR0100946A/pt not_active IP Right Cessation
- 2001-03-09 JP JP2001066202A patent/JP3529736B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1132388A2 (en) | 2001-09-12 |
| CA2339528C (en) | 2007-05-08 |
| JP3529736B2 (ja) | 2004-05-24 |
| EP1132388A3 (en) | 2004-03-03 |
| JP2001278866A (ja) | 2001-10-10 |
| CA2339528A1 (en) | 2001-09-09 |
| US20020002138A1 (en) | 2002-01-03 |
| US6531449B2 (en) | 2003-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0100946A (pt) | Metabólitos de hexahidropirazolo[4,3-c] piridina | |
| BRPI0418270A (pt) | métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica | |
| IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
| WO2002015903A3 (de) | Neue pharmazeutische zusammensetzung zur verabreichung von n-0923 | |
| EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| HRP20041211B1 (hr) | Topikalno primjenjivi farmaceutski pripravak | |
| NO20062004L (no) | Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav | |
| MXPA04000456A (es) | Analogos de prostaglandina como agonistas del receptor ep4. | |
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| US20190111052A1 (en) | Methods of treating a neurodegenerative disease | |
| US20080214599A1 (en) | Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases | |
| CA2360313A1 (en) | Glucocorticoid receptor modulators | |
| YU37203A (sh) | Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti | |
| CA2442478A1 (en) | Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation | |
| AR044775A1 (es) | Composiciones farmaceuticas de atorvastatina | |
| WO2005002582A3 (en) | Trp-p8 active compounds and therapeutic treatment methods | |
| CA2360308A1 (en) | Glucocorticoid receptor modulators | |
| WO2005102381A1 (ja) | カテプシンｋ阻害薬およびpth類を併用することを特徴とする骨密度増加剤 | |
| DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
| JP6377620B2 (ja) | グルコース取り込みを改善するための組成物および方法 | |
| NO20061702L (no) | Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist | |
| ES2271229T3 (es) | Uso de antagonistas mglur5 para el tratamiento de condiciones pruriticas. | |
| CA2402099A1 (en) | Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment | |
| EP3134417B1 (en) | Small molecule analogs of e4orf1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A, 9A E 10A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011. |